Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

DiaMedica Therapeutics Inc. - Common Stock (NQ:DMAC)

6.430 -0.090 (-1.38%)
Streaming Delayed Price Updated: 10:13 AM EDT, Aug 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about DiaMedica Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
DiaMedica (DMAC) Q2 2026 Earnings Call Transcript ↗
ReMEDy2 stroke trial nears interim analysis with 85% enrollment complete. 
Via The Motley Fool
Topics Earnings
News headline image
DiaMedica Therapeutics Q2 Earnings Call Highlights ↗
DiaMedica Therapeutics (NASDAQ:DMAC) said its second-quarter progress centered on advancing DM199 across early-onset fetal growth restriction (FGR), preeclampsia and acute ischemic stroke, while the... 
Via MarketBeat
Topics Earnings
News headline image
DiaMedica Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights
From DiaMedica Therapeutics Inc.
Via Business Wire
DiaMedica Therapeutics (NASDAQ:DMAC) Posts Wider Q1 Loss but Clinical Catalysts Fuel Stock Resilience ↗
Via Chartmill
News headline image
Earnings Scheduled For November 12, 2025 ↗
 
Via Benzinga
News headline image
DiaMedica Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Business Update August 11, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica (DMAC) Q4 2025 Earnings Transcript ↗
DiaMedica (DMAC) Q4 2025 Earnings Transcript 
Via The Motley Fool
Topics Intellectual Property
News headline image
DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica (DMAC) Q1 2026 Earnings Transcript ↗
DiaMedica (DMAC) Q1 2026 Earnings Transcript 
Via The Motley Fool
Topics Death
News headline image
DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
RedChip's Biotech Virtual Investor Conference Replays Now Available
Via ACCESS Newswire
News headline image
RedChip's April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms
Via ACCESS Newswire
News headline image
DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
Top Wall Street Forecasters Revamp DiaMedica Therapeutics Expectations Ahead Of Q4 Earnings ↗
DiaMedica Therapeutics (NASDAQ: DMAC) will release Q4 earnings on March 30. Analysts expect a quarterly loss of 18 cents per share. Stock fell 0.9% on Friday. 
Via Benzinga
News headline image
DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia
From DiaMedica Therapeutics Inc
Via Business Wire
News headline image
DiaMedica Therapeutics to Participate in Upcoming March Investor Conferences
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's After-Market Session ↗
 
Via Benzinga
News headline image
DiaMedica Therapeutics Inc (NASDAQ:DMAC) Reports Q3 2025 Earnings and Clinical Progress ↗
DiaMedica reports Q3 2025 results, advancing DM199 for stroke and preeclampsia. The company has a cash runway into H2 2027 to fund clinical trials. 
Via Chartmill
News headline image
DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
From DiaMedica Therapeutics Inc.
Via Business Wire
News headline image
An Overview of DiaMedica Therapeutics's Earnings ↗
 
Via Benzinga
News headline image
DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London
From DiaMedica Therapeutics Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.